Suri Chitra, Jones Pamela F, Patan Sybill, Bartunkova Sona, Maisonpierre Peter C, Davis Samuel, Sato Thomas N, Yancopoulos George D
Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
Cell. 1996 Dec 27;87(7):1171-80. doi: 10.1016/s0092-8674(00)81813-9.
Vascular endothelial growth factor (VEGF), which acts via members of a family of endothelial-specific receptor tyrosine kinases, is the only factor that has been shown definitively to play a role in the formation of the embryonic vasculature. Only one other family of receptor tyrosine kinases, comprising TIE1 and TIE2, is largely endothelial cell specific. We have recently cloned a ligand for TIE2, termed Angiopoietin-1. Here we show that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that Angiopoietin-1 is a primary physiologic ligand for TIE2 and that it has critical in vivo angiogenic actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGF. Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme.
血管内皮生长因子（VEGF）通过内皮特异性受体酪氨酸激酶家族成员发挥作用，是唯一已被明确证明在胚胎血管系统形成中起作用的因子。仅另一类受体酪氨酸激酶家族，包括TIE1和TIE2，在很大程度上是内皮细胞特异性的。我们最近克隆了一种TIE2的配体，称为血管生成素-1。在此我们表明，经基因工程改造而缺乏血管生成素-1的小鼠表现出血管生成缺陷，这让人想起先前在缺乏TIE2的小鼠中所见到的缺陷，这表明血管生成素-1是TIE2的主要生理配体，并且它具有与VEGF不同的关键体内血管生成作用，而这些作用在用于表征VEGF的经典体外试验中未得到体现。血管生成素-1似乎在介导内皮细胞与周围基质及间充质之间的相互作用中起关键作用。
